文献速递外周动脉疾病

少数族裔、女性及组织缺损与CLTI血运重建后再入院风险相关

Racial and ethnic minority groups, female sex, and tissue loss are associated with increased risk for hospital readmission following revascularization for chronic limb-threatening ischemia.
PubMed 文献 · J Vasc Surg · 2025-06-03

该研究基于2020至2022年247例CLTI血运重建患者,发现53%在1年内再入院,常见原因为伤口感染和组织破损。多变量分析显示少数族裔、女性及组织缺损指征与30天再入院相关,1年时仅少数族裔和组织缺损指征仍相关。

要点

  • CLTI血运重建后1年再入院率达53%,主要为伤口感染和组织破损。
  • 少数族裔、女性及组织缺损指征与30天再入院风险升高相关。
  • 1年时仅少数族裔和组织缺损指征与再入院风险升高相关。

核心结论

  • CLTI血运重建后再入院率高,多数再入院为潜在可干预因素,少数族裔、女性及组织缺损患者风险最高。

研究设计与样本

  • 基于Current Procedural Terminology编码识别2020年1月6日至2022年5月25日期间247例CLTI血运重建患者,收集人口学、手术及1年结局数据,采用单变量和多变量模型分析再入院相关因素。

主要发现

  • 247例中130例(53%)在1年内再入院,30天和1年再入院最常见指征为伤口感染和组织破损(分别为48.3%和37.7%)及新发静息痛或组织缺损(分别为13.8%和20.8%)。
  • 30天和1年再入院中分别有96.6%和96.9%为潜在可干预因素(伤口感染和组织破损、新发静息痛或组织缺损、移植物血栓、脓毒症、心肌梗死)。

临床怎么用

  • 术后再入院主要因伤口感染和新发静息痛或组织缺损,多数为潜在可干预因素。
  • 少数族裔和女性患者因组织缺损行血运重建后再入院风险最高,数据支持针对这些高危人群开展干预研究。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Unplanned hospital readmission following surgery for peripheral arterial disease is among the highest in all diagnosis-related groups. Although previous studies have examined readmissions in certain subgroups, such as for patients undergoing lower extremity bypass, few have examined longer term readmissions for those with the most severe form of peripheral arterial disease, chronic limb-threatening ischemia (CLTI). Among patients with CLTI undergoing revascularization, we sought to outline rates of readmission beyond 30 days up to 1 year and identify patient and procedural characteristics associated with readmission. METHODS: We identified patients by Current Procedural Terminology codes from January 6, 2020, to May 25, 2022, and collected demographic, operative, and 1-year outcomes data. We used univariate and multivariable modeling to assess factors associated with hospital readmission. RESULTS: Of the 247 patients who underwent intervention for CLTI, 130 patients (53%) were readmitted within 1 year, primarily for revascularization-related problems. The most common indications for readmission within 30 days and 1 year were wound infection and tissue breakdown (48.3% and 37.7%, respectively) and new rest pain or tissue loss (13.8% and 20.8%, respectively). The only cause of readmission considered nonmodifiable was undergoing a staged procedure. Overall, 96.6% and 96.9% of readmissions within 30 days and 1 year were potentially modifiable (ie, wound infection and tissue breakdown, new rest pain or tissue loss, graft thrombosis, sepsis, and myocardial infarction). After multivariable adjustment, racial and ethnic minority groups (odds ratio [OR], 2.6; P = .009), female sex (OR, 2.1; P = .031), and tissue loss as an indication (OR, 4.1; P = .0002) were associated with readmission within 30 days. At 1 year, only racial and ethnic minority status (OR, 2.6; P = .007) and a tissue loss indication (OR, 2.1; P = .011) were associated with readmissions. Patient age, comorbidity burden, area deprivation index, and intervention type (endovascular vs open) were not significantly associated with 30-day or 1-year readmissions. Racial and ethnic minority groups (P = .014), female sex (P = .05), acute kidney injury (P = .014), and index hospital length of stay (P = .009) were associated with multiple readmissions. Number of readmissions was not associated with risk of major limb amputation. CONCLUSIONS: Postoperative readmission among patients with CLTI is high and occurs primarily for wound infections and new rest pain or tissue loss. Overall, the majority of readmissions were for potentially modifiable factors. Racial and ethnic minority groups and female patients undergoing revascularization for tissue loss are at greatest risk for readmissions. These data support the investigation of interventions targeting these high-risk populations.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Ueland WR, Javed MJ, Spinosa M, et al. Racial and ethnic minority groups, female sex, and tissue loss are associated with increased risk for hospital readmission following revascularization for chronic limb-threatening ischemia. J Vasc Surg. 2025. PMID: 40473004. doi:10.1016/j.jvs.2025.05.203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。